Dr. Thomas B. Powell, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 532
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Medical University of South Carolina College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
SC license 26824 -
Internal Medicine Physician
SC license 26824
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Prisma Health Richland Hospital Columbia, SC
- Lexington Medical Center West Columbia, SC
- Prisma Health Baptist Columbia, SC
- Musc Health Columbia Medical Center Downtown Columbia, SC
- Prisma Health Baptist PArkridge Columbia, SC
Medical groups
- Columbia Nephrology Associates PA (33 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 532
- Services billed
- 2,697
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Kidney function blood test panel | 215 | 140 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 212 | 140 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 177 | 95 |
| Established patient office or other outpatient visit, 30-39 minutes | 176 | 136 |
| Insertion of needle into vein for collection of blood sample | 148 | 106 |
| Parathormone (parathyroid hormone) level | 142 | 112 |
| Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist | 120 | 99 |
| Total protein level, urine | 85 | 78 |
| Creatinine level to test for kidney function or muscle injury | 85 | 78 |
| Fluoroscopic guidance for insertion or removal of central vein access device | 83 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calcitriol Other prescribers in Columbia, SC | 53 |
| Furosemide Other prescribers in Columbia, SC | 44 |
| Amlodipine Besylate Other prescribers in Columbia, SC | 41 |
| Lisinopril Other prescribers in Columbia, SC | 14 |
| Allopurinol Other prescribers in Columbia, SC | 13 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Columbia, SC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 42 payments worth $873 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $301 |
|---|---|
| Bard Peripheral Vascular, Inc. | $101 |
| Otsuka America Pharmaceutical, Inc. | $75.66 |
| Mallinckrodt Hospital Products Inc. | $57.50 |
| Calliditas Therapeutics US Inc. | $43.53 |
| Genzyme Corporation | $41.51 |
| Scpharmaceuticals Inc. | $32.71 |
| Fresenius USA Marketing, Inc. | $31.72 |
| Food and Beverage | $873 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $187,483 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidne…
Vertex Pharmaceuticals Incorporated - A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.